Inteum Company
Links
seedsprint
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Search Results - biologics
16
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Antibodies against CD5L for therapeutic and diagnostic uses
Provided herein are anti-CD5L monoclonal antibodies. Further provided herein are methods of use thereof for the treatment of a disease or disorder, such as cancer. UTHealth Ref. No.: 2020-0016 Inventors: Dr. Zhiqiang An and Dr. Ningyan Zhang at UTHealth; Dr. Anil Sood at UT M.D. Anderson Cancer Center Patent Status: PCT application PCT/US2021/025429...
Published: 5/28/2024
|
Inventor(s):
Zhiqiang An
,
Ningyan Zhang
,
Anil Sood
Keywords(s):
Category(s):
Biologics
,
Oncology
,
Therapeutics
Monoclonal Antibodies Against PCDH7 for Therapeutic and Diagnostic Use
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-associated deaths worldwide. UTHealth researchers discovered that the cell surface protein Protocadherin 7 (PCDH7) is highly expressed in NSCLC and promotes lung cancer development. Inventors at UTH in collaboration with Dr. O’Donnell’s group at UTSW have discovered a panel...
Published: 5/28/2024
|
Inventor(s):
Zhiqiang An
,
Ningyan Zhang
,
Kathryn O'Donnell
Keywords(s):
Category(s):
Diagnostics
,
Oncology
,
Therapeutics
,
Biologics
Monoclonal antibodies against human endotrophin for therapeutic and diagnostic use.
Background Studies have shown that endotrophin, the carboxy-terminal cleavage product of the COL6α3 chain, has potent effects on transformed mammary ductal epithelial cells in rodents. It is abundantly expressed in adipose tissue and is a chemoattractant for macrophages, exerts effects on endothelial cells and enhances the progression through...
Published: 5/2/2024
|
Inventor(s):
Zhiqiang An
,
Ningyan Zhang
,
Philipp Scherer
Keywords(s):
Category(s):
Biologics
,
Oncology
,
Therapeutics
Monoclonal Antibodies Binding to Transferrin Receptor (TfR) for Therapeutic Protein Delivery across Blood-Brain Barrier
Blood-brain barrier (BBB) limits brain entry and is one of the major hurdles in developing antibody and protein-based therapeutics for central nervous system (CNS) diseases. UTHealth researchers identified and engineered monoclonal antibodies binding to transferrin receptor (TfR) but not affecting transferrin (Tf) binding to TfR. An engineered monovalent...
Published: 5/2/2024
|
Inventor(s):
Zhiqiang An
Keywords(s):
Category(s):
Drug Delivery
,
Therapeutics
,
Neurology/Neurosurgery
,
Oncology
,
Biologics
TREM2 Monoclonal Antibody for Therapeutic and Diagnostic Use
Triggering Receptor Expressed on Myeloid cells 2 (TREM2) plays a key regulatory role in Alzheimer’s disease (AD) by controlling microglia activation and metabolic activities in brain tissues. Previous studies in rodent models of AD have shown that mice with increased TREM2 expression have reduced amyloid pathology. UTHealth inventors created and...
Published: 5/2/2024
|
Inventor(s):
Zhiqiang An
Keywords(s):
Category(s):
Therapeutics
,
Diagnostics
,
Biologics
,
Neurology/Neurosurgery
Synthetic Antifungal Peptides
Novel antifungal compositions that inhibit fungal growth which have both medical and non-medical utility and applications Inventors at the University of Texas Health Science Center at Houston have developed a series of novel peptide compounds to inhibit fungal growth. The peptides are based on the bacteriocin EntV, which is secreted by Enterococcus...
Published: 5/2/2024
|
Inventor(s):
Danielle Garsin
,
Michael Lorenz
Keywords(s):
Category(s):
Biologics
,
Therapeutics
LGR4 Specific Monoclonal Antibodies and Their Use
Researchers at UTHealth have isolated and characterized monoclonal antibodies as well as antibody fragments that specifically binding to LGR4, a 7TM receptor that is highly expressed in major types of solid tumors, including but not limited to colorectal cancer, non-small cell lung cancer, and ovarian cancer. These LGR4 specific monoclonal antibodies...
Published: 8/15/2023
|
Inventor(s):
Qingyun (Jim) Liu
Keywords(s):
Category(s):
Biologics
,
Oncology
,
Therapeutics
,
Diagnostics
,
Research Materials
Mutants and Drug Conjugates of R-Spondin Polypeptides for Cancer Therapy
R-spondins (RSPOs) are secreted proteins with critical roles in cancer development through binding to LGRs and RNF43/ZNRF3 and potentiating Wnt signaling. Various RSPO mutants were discovered that bind to LGRs but no longer function in Wnt signaling. Fc fusion protein of the RSPO mutants, so called RSPO peptibodies, were conjugated with cytotoxic...
Published: 8/15/2023
|
Inventor(s):
Qingyun (Jim) Liu
Keywords(s):
Category(s):
Biologics
,
Oncology
,
Therapeutics
Monoclonal Antibodies Against Oncostatin M Receptor (OSMR) for Therapeutic and Diagnostic Use
Researchers from UTHealth and The Medical College of Wisconsin have collaborated to reveal the role of OSMR in promoting ovarian cancer cell proliferation and metastasis through activation of STAT3 signaling, as well as illuminated the preclinical efficacy of antibody-based OSMR targeting for ovarian cancer treatment. More particularly, researchers...
Published: 5/2/2024
|
Inventor(s):
Zhiqiang An
Keywords(s):
Category(s):
Diagnostics
,
Therapeutics
,
Biologics
,
Oncology
Monoclonal Antibodies Against Chitinase 3-like-1 (Chi3l1) for Therapeutic and Diagnostic Use
Researchers at UTHealth have unveiled a critical role of Chi3l1 in hepatic platelet recruitment during acetaminophen (APAP)-induced liver injury (AILI) using murine models of AILI and concanavalin A (Con A)-induced hepatitis. Significantly, they have developed anti-Chi3l1 monoclonal antibodies and demonstrated the feasibility of targeting CHI3L1...
Published: 8/15/2023
|
Inventor(s):
Zhiqiang An
,
Changqing (Cynthia) Ju
Keywords(s):
Category(s):
Biologics
,
Therapeutics
,
Oncology
1
2